Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. (Q42666923)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

main subject

phase II clinical trial

0 references

regorafenib

1 reference

ChEBI release 2020-05-28

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Heikki Joensuu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Marek Wojtukiewicz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

10

Kate Fife

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

11

Petri Bono

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Tim Eisen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Paul D Nathan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Peter G Harper

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Steve Nicholson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Amit Bahl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Piotr Tomczak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Seppo Pyrhonen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jane Boxall

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Andrea Wagner

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Michael Jeffers

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Tiffany Lin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

6 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1055-1062

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22959186%20AND%20SRC:MED&resulttype=core&format=json

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Epidemiology of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

EORTC-GU group expert opinion on metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

The paracrine role of Tie-2-expressing monocytes in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970364-9

7 January 2021